Search Results

By Matthew Stenger  / Thursday, August 1, 2019 4:46 PM

Durvalumab With or Without Tremelimumab in Metastatic Pancreatic Cancer

In the first stage of a phase II trial reported in JAMA Oncology, O’Reilly et al found poor activity of durvalumab with or without tremelimumab in metastatic pancreatic ductal adenocarcinoma. Owing to the lack of efficacy, study expansion was not pursued.   The lead-in open-label safety ...